Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
RIGL Stock Chart & Stats
$25.96
-$0.99(-5.79%)
At close: 4:00 PM EST
$25.96
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$15.50 - $52.24
Previous CloseN/A
Volume99.93K
Average Volume (3M)369.54K
Market Cap
$479.56M
Enterprise Value$492.28M
Total Cash (Recent Filing)$154.96M
Total Debt (Recent Filing)$53.30M
Price to Earnings (P/E)2.1
Beta2.03
Next Earnings
May 05, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.54
Shares Outstanding18,473,130
10 Day Avg. Volume406,349
30 Day Avg. Volume369,536
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.67
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda3.85
Forecast
1Y Price Target
$52.00Price Target Upside100.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)3.97
Revenue Forecast (FY)$279.31M
Bulls Say, Bears Say
Bulls Say
Clinical Development: R289 Dose ExpansionAdvancement of the IRAK inhibitor R289 into dose expansion with enrollment moving toward dose selection and plans for an FDA discussion could de‑risk the program and enable a path toward a registrational study.
Commercial PerformanceStrong commercial uptake of Tavalisse and Rezlidhia, together with broadly stable Gavreto sales and product revenues above analyst estimates, supports expectations for sustained top-line growth.
Tax-driven Cash FlexibilityRealization of deferred tax assets alongside projected positive net income is expected to reduce federal cash tax outlays and provide financial flexibility to support pipeline investments.
Bears Say
Accounting Distortion From Non-cash Tax BenefitReported earnings were materially boosted by a large non‑cash deferred tax benefit, creating a notable gap between accounting results and underlying operational performance.
Clinical Safety And Tolerability RisksFrequent serious treatment‑related adverse events observed in clinical trials raise safety and tolerability concerns that could limit clinical adoption or complicate regulatory review.
Recurring Tax Expense PressureRecording federal and state income tax expenses through the income statement each quarter is expected to reduce reported net income and earnings per share relative to recently reported levels.
Rigel News
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $15.50 and its highest was $52.24 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $479.56M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is May 05, 2026 which is in 43 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Mar 03, 2026. The company reported $13.54 earnings per share for the quarter, beating the consensus estimate of $1.201 by $12.339.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.84.
How many shares outstanding does Rigel have?
Rigel has 18,473,130 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $13.54 in its last earnings report, beating expectations of $1.201. Following the earnings report the stock price went down -10.267%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$52.00 (100.31% Upside)
$52.00 (100.31% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 97.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $145.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.44%
12-Months-Change
Fundamentals
Return on Equity
240.83%
Trailing 12-Months
Asset Growth
13.67%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Rigel Pharmaceuticals' strong financial performance, significant increases in revenue and net product sales, and advancements in their drug development pipeline. Despite the termination of a specific CNS program by Eli Lilly, the overall tone was positive, focusing on growth and expansion opportunities.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$52.00
▲(100.31% Upside)
Technical Analysis
Ownership Overview
3.07% Insiders
27.98% Mutual Funds
19.27% Other Institutional Investors
29.07% Public Companies and Individual Investors